Hair Loss News and Research

RSS

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

The good news widely reported this morning of positive results from a clinical drug trial at Boston Children's Hospital for the previously "untreatable" rapid aging disorder in children known as progeria has its scientific roots in basic biology discoveries made in recent years.

26 Sep 2012

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

CSHL publishes genome-wide analysis of transcripts produced within human cells

Most people understand genes to be specific segments of DNA that determine traits or diseases that are inherited. Textbooks suggest that genes are copied into RNA molecules, which are then used as templates for making protein - the highly diverse set of molecules that act as building blocks and engines of our cells. The truth, it now appears, is not so simple.

6 Sep 2012

Key facts about polycystic ovary syndrome

September marks Polycystic Ovary Syndrome (PCOS) awareness month and with this condition affecting millions of women in the world, there are some key facts about the condition to highlight that can affect a women's fertility when suffering with the disorder.

6 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012

Depressive symptoms, suicidal thoughts more prevalent among former finasteride users

New research, to be published in the Journal of Clinical Psychiatry, finds that men who developed persistent sexual side effects while on finasteride (Propecia), a drug commonly used for male pattern hair loss, have a high prevalence of depressive symptoms and suicidal thoughts.

8 Aug 2012

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.

24 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012

Tips to maintain healthy hair

Want more good hair days? Dermatologists say how you wash your hair and the products you use could go a long way in maintaining smooth, shiny hair.

10 Jul 2012

Novel system to treat hair loss receives CE Mark approval

Restoration Robotics, Inc., a privately-held medical device company, today announced its revolutionary ARTAS System received CE Mark Certificate to market in the European Union. The ARTAS System is the first physician controlled, computer assisted technology that allows harvesting individual follicular units directly from the scalp.

9 Jul 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

Six novel genetic associations for early onset male pattern baldness

Using data from its unique online research platform, 23andMe, a leading personal genetics company, has contributed to the finding of six novel genetic associations for early onset male pattern baldness (androgenetic alopecia) in a genome-wide association study now published online in the journal PLoS Genetics.

20 Jun 2012

Drug shows promise as skin cancer treatment

A new drug for a type of skin cancer caused by a rare genetic disease can not only substantially shrink the tumors, but can also prevent the growth of new cancers, US investigators have discovered.

15 Jun 2012

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company's novel, proprietary, recombinant protein.

13 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

A revolutionary clinical study has demonstrated the effectiveness of a new drug, vismodegib, in dramatically shrinking and preventing the formation of basal cell skin cancers - the most common cancer in the United States - in patients with basal cell nevus syndrome (BCNS), a rare genetic condition that causes hundreds to thousands of skin cancers primarily treated by surgical removal.

7 Jun 2012

T-DM1 better than standard therapy in controlling breast cancer

A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.

5 Jun 2012

Scars, disfigurement and hair loss from childhood cancer can affect adult quality of life

Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced quality of life in adulthood, according to a new study led by a Northwestern Medicine advanced practice nurse, Karen Kinahan, and based on data from the Childhood Cancer Survivor Study.

25 May 2012

New strategy can reactivate genes that cause cancer tumors to shrink and die

A team of scientists has developed a promising new strategy for "reactivating" genes that cause cancer tumors to shrink and die. The researchers hope that their discovery will aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs.

22 May 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

Hair Loss News and Research

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

CSHL publishes genome-wide analysis of transcripts produced within human cells

Key facts about polycystic ovary syndrome

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Depressive symptoms, suicidal thoughts more prevalent among former finasteride users

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Tips to maintain healthy hair

Novel system to treat hair loss receives CE Mark approval

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Six novel genetic associations for early onset male pattern baldness

Drug shows promise as skin cancer treatment

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

T-DM1 better than standard therapy in controlling breast cancer

Scars, disfigurement and hair loss from childhood cancer can affect adult quality of life

New strategy can reactivate genes that cause cancer tumors to shrink and die

Apigenin effective against human breast cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News